Matan Arbel-Groissman (@ArbleMatan) profile picture

Postdoc working on epigenetics in prostate cancer. Whatever I write is my opinion and I do not represent anybody.

Takoma Park
Joined October 2019
Photo by Matan Arbel-Groissman (@ArbleMatan)Photo by Matan Arbel-Groissman (@ArbleMatan)Photo by Matan Arbel-Groissman (@ArbleMatan)Photo by Matan Arbel-Groissman (@ArbleMatan)Photo by Matan Arbel-Groissman (@ArbleMatan)Photo by Matan Arbel-Groissman (@ArbleMatan)Photo by Matan Arbel-Groissman (@ArbleMatan)Photo by Matan Arbel-Groissman (@ArbleMatan)Photo by Matan Arbel-Groissman (@ArbleMatan)Photo by Matan Arbel-Groissman (@ArbleMatan)
Matan Arbel-Groissman retweeted
No way
BREAKING: Colossal Biosciences, the startup working to bring extinct animals back to life, accuses a former employee of stealing company de-extinction secrets.
248
4,714
70
37,990
609,596
Matan Arbel-Groissman retweeted
Our best defense against bioterrorism is that biology makes a bad weapon. Malicious actors effectively never choose biology as a tool to cause harm This review surveys all documented biocrimes since 1763. They found 19 events total in more than 250 years. 99.2% of all biocrime deaths were the actions of the Imperial Army of Japan in World War 2. Exluding those, they found 79 total deaths in total. That's < 1 death per year Bioterrorism kills fewer people than sharks. Fewer people than falling coconuts. Fewer people than vending machines. It simply isn't a thing I know that the Killer AI Virus crowd will object that the purpose of biosecurity is to defend against hypothetical future threats, not historically documented threats But history can still inform our biosecurity policy. If you believe that the world is full of people who want to kill with biology, you are wrong. If you base your biosecurity policy on that belief, you will build the wrong safeguards A rational, evidence-based biosecurity policy needs to begin from the reality that biology makes a bad weapon and focus on ways to make it an even worse weapon academic.oup.com/milmed/advaโ€ฆ
27
44
11
213
23,014
ืกื•ืฃ ืกื•ืฃ ื™ืจื“ ื’ืฉื, ื•ื”ืจื™ื— ื”ืื•ืคื™ื™ื ื™ ื ื™ืฉื ื‘ืื•ื•ื™ืจ: ืฉื™ืœื•ื‘ ืฉืœ ืฉืœื•ืฉื” ืจื™ื—ื•ืช. ืฉื ื™ื™ื ื‘ื™ื•ืœื•ื’ื™ื™ื ื•ื”ืฉืœื™ืฉื™ "ืžื˜ืื•ืจื•ืœื•ื’ื™". ื”ืจื™ื— ื”ืจืืฉื•ืŸ ื ื•ื‘ืข ืžื—ื™ื™ื“ืงื™ื ื‘ืื“ืžื”, ื”ืžืชืขื•ืจืจื™ื ืœืคืขื™ืœื•ืช ื‘ืขืงื‘ื•ืช ื”ื’ืฉื. ื”ื ืžืคืจื™ืฉื™ื ื—ื•ืžืจ ื ื“ื™ืฃ ื”ืžื›ื•ื ื” ื’ืื•ืกืžื™ืŸ (Geosmin). ื”ืจื™ื— ื”ืฉื ื™ ืžืงื•ืจื• ื‘ืฉืžื ื™ื ืืจื•ืžื˜ื™ื™ื ืฉื”ื•ืคืจืฉื• ืœืื“ืžื” ืขืœ ื™ื“ื™ ืฆืžื—ื™ื.
10
4
1
212
10,066
ืื—ื“ ื”ื“ื‘ืจื™ื ื”ืžืขื ื™ื™ื ื™ื ื‘ืฆื‘ืขื™ ื”ืฉืœื›ืช ื”ื•ื ื”ืฆื‘ืข ื”ืื“ื•ื. ื”ืฆื”ื•ื‘ ื ื•ืฆืจ ื›ืฉื”ืขืœื” ืžืคืกื™ืง ืœื™ื™ืฆืจ ื›ืœื•ืจื•ืคื™ืœ ื™ืจื•ืง ืœืงืจืืช ื”ื—ื•ืจืฃ ื”ืงืจ ื•ื”ืžื•ืฉืœื’ ืฉืœ ืฆืคื•ืŸ ืืžืจื™ืงื” ื•ื›ืš ื ื—ืฉืคื™ื ืงืจื˜ื ื•ืื™ื“ื™ื ืฉื”ื ื”ืคื™ื’ืžื ื˜ื™ื ื”ืฆื”ื•ื‘ื™ื, ืœืžืฉืœ ื‘ืฆืคืฆืคื”. ืื‘ืœ ืืช ื”ืฆื‘ืข ื”ืื“ื•ื ืฆืจื™ืš ืœื™ื™ืฆืจ ื–ืžืŸ ืงืฆืจ ืœืคื ื™ ืฉื”ืขืœื” ืžืช. ื”ืื“ื•ื ื”ื•ื ืคื™ื’ืžื ื˜ ื‘ืฉื ืื ืชื•ืฆื™ืื ื™ืŸ ืœืžืฉืœ
1
1
24
819
Matan Arbel-Groissman retweeted
The first 6 months of a PhD are spent discovering the field. The next 4 years are spent discovering why everyone avoided your particular corner of it.
17
311
21
4,806
69,968
Matan Arbel-Groissman retweeted
Excited to share our recent publication in @NatureComms! We started by trying to make people stop associating the money rewards they obtain with irrelevant features of their behavior. In the first experiment, we used clear instructions framed as a story, and it didn't help...
1
10
2
27
1,581
Yep, that's me. you're probably wondering how I got there. A thread about our newst paper on how transfer of mRNAs through tunneling nanotubes can rescue a disease penotype (in cell culture. but, spoiler, we have new data it also works in mice): 1/12
5
4
1
36
4,771
Replying to @MaximRubinBlum
@MaximRubinBlum ื“"ืจ ืžืงืกื™ื ืจื•ื‘ื™ืŸ ื‘ืœื•ื ื—ื•ืงืจ ืืช ืคืจื™ื—ืช ื”ื—ื™ื™ื“ืงื™ื ื”ื—ืจื™ื’ื” ืœื—ื•ืคื™ื ื• ื•ืกื™ืคืจ ื”ื™ื•ื ื‘ืžืกื’ืจืช ื”ื›ื ืก ืฉืœ ื”ื—ื‘ืจื” ื”ื™ืฉืจืืœื™ืช ืœืžื™ืงืจื•ื‘ื™ื•ืœื•ื’ื™ื” ืฉื‘ืคืจื™ื—ื” ื™ืฉ ื›ื›ื”"ื  ื—ื™ื™ื“ืง ื•ื›ืžื” ืืื•ืงืจื™ื•ื˜ื™ื™ื ื–ืขื™ืจื™ื ื•ืฉื‘ืื•ืคืŸ ืžืคืชื™ืข ืžื•ืฆืื™ื ืฉื ื’ื ื“ื "ื ืฉืœ ื—ื™ื™ื“ืงื™ ืžื™ื ืžืชื•ืงื™ื. ืœื ื‘ืจื•ืจ ืื ื”ื—ื™ื™ื“ืงื™ื ื”ืืœื• ื—ื™ื™ื ืื• ืฉืืœื• ืฉืืจื™ื•ืช ืฉืœ
2
2
1
29
2,110
ื”ื—ื•ื“ืฉ ื”ืื—ืจื•ืŸ ื”ื™ื” ื›ื™ืฉืœื•ืŸ ืื—ืจื™ ื›ื™ืฉืœื•ืŸ ืœืชืขืฉื™ื™ืช ื”ืชืจื•ืคื•ืช ื›ื ื’ื“ ื”ืชืงืคื™ ืœื‘ ื•ืื•ืœื™ ืœืชืขืฉื™ื™ืช ื”ืคืืจืžื” ื‘ื›ืœืœื™. ืขื‘ื•ื“ื•ืช ื“ื•ืงื˜ื•ืจื˜ ื”ื•ืœื›ื•ืช ืœื”ื™ื›ืชื‘ ืขืœ ื”ื—ื•ื“ืฉ ื”ื–ื”. ืื ืฉื™ื (ื›ื•ืœืœ ืื ื™) ืฆืจื™ื›ื™ื ืขืฉืจืช ื™ืžื™ ืชืฉื•ื‘ื” ื›ื“ื™ ืœื”ื‘ื™ืŸ ืžื—ื“ืฉ ืžื” ืœืขื–ืื–ืœ ืงื•ืจื” ื›ืืŸ. ืฉืจืฉื•ืจ ืžืฉื‘ืจื™ ๐Ÿงต๐Ÿ‘‡
17
12
1
299
18,334
Matan Arbel-Groissman retweeted
Yes it sucks to spend $200 on a bad antibody. That undoubtedly adds to the cost of doing research. But the total costs of this fraud are *MUCH* larger. Most people recognize the enormous *time* cost of this fraud - every basic scientist has wasted days trying to make bad antibodies work. But what productive use could that time have been used for? What discoveries *werenโ€™t* made because of this? (Opportunity cost) Itโ€™s even harder to measure the cost of false positives. How many drug candidates made it to phase 1 testing because of bad antibodies? Is this why so many drugs fail in phase 1? How many patients were harmed by ineffective therapies developed using bad antibodies? (Human cost) How many hundreds of billions do failed phase 1 studies add to the cost of drug development, and indirectly to overall healthcare costs? Weโ€™re all paying for this fraud whether youโ€™ve ever pipetted or not. The companies that are deliberately selling bad antibodies should be held accountable for these costs.
"More than 18,000 questionable images found in antibody catalogues of 15 companies" - It's stuff like this that makes bio research so slow
10
69
5
464
41,144
Matan Arbel-Groissman retweeted
ื™ืฉ ืœื™ ื—ื‘ืจื” ืกื•ืคืจ ื›ืฉืจื•ื ื™ืช, ืฉื—ื•ื–ืจืช ืœืืจืฅ ืขื•ื“ ื—ื•ื“ืฉื™ื™ื ืžืคื•ืกื˜ ื‘ื”ืจื•ืืจื“ ื•ืžื—ืคืฉืช ืขื‘ื•ื“ื”! ื™ืฉ ืœื” ื ืกื™ื•ืŸ ื‘ื“ื‘ืจื™ื ืฉืœ ื‘ื™ื•ืœื•ื’ื™ื ื›ืžื• ืžื—ืงืจ ืคื•ืจื™ื•ืช, ืืคื™ื’ื ื˜ื™ืงื” ื”ื™ืกื˜ื•ื ื™ื ื•ื”ื˜ืจื•ื›ืจื•ืžื˜ื™ืŸ, ืžื•ื“ืœื™ ื—ื™ื•ืช, ืžื™ืงืจื•ืกืงื•ืคื™ื”, ืื™ืžื’ืณื™ื ื’ ื•ื’ื ื˜ื›ื ื™ืงื•ืช ืฉื•ื ื•ืช ื‘ืžื•ืœืงื•ืœืจื™ืช ื–ืžื™ื ื” ืœืขื‘ื•ื“ื” ืžื“ืฆืžื‘ืจ ืื ืืชื ืžื›ื™ืจื™ื ื—ื‘ืจื•ืช ืฉืžื—ืคืฉื•ืช ืืฉืžื— ืœืงื™ืฉื•ืจ
3
8
62
2,254
Matan Arbel-Groissman retweeted
ืฉื ื” ืœืžื•ืช ื‘ืจืง ืฆื— ื–"ืœ. ื ื ืกื” ืœืœืžื•ื“ ืžืฉื”ื• ืžื”ืืกื•ืŸ. ื”ืื‘ื•ืœื•ืฆื™ื” ืื™ื ื” ืชื”ืœื™ืš ืชื‘ื•ื ื™, ื•ืœื›ืŸ ื ื“ืจืฉื•ืช ืœื” ืœืขืชื™ื ืžืื•ืช ืžื™ืœื™ื•ื ื™ ืฉื ื™ื ื›ื“ื™ ืœืกื’ื•ืจ ืžืขื’ืœ. ื›ืš ืงืจื” ืขื ืžื—ื–ื•ืจ ื”ื“ื ืฉืœ ื‘ืขืœื™-ื”ื—ื•ืœื™ื•ืช. ืžื—ื–ื•ืจ ื”ื“ื ืฉืœ ื”ื“ื’ ื”ื•ื ืคืฉื•ื˜ ื•ื™ืขื™ืœ: ื“ื ืžื•ื–ืจื ืžื”ืœื‘ ื”ื“ื•-ื—ื“ืจื™ ืืœ ื”ื–ื™ืžื™ื, ืžืชืจื•ื•ื” ื‘ื—ืžืฆืŸ (ืื“ื•ื), ืžืžืฉื™ืš ืžืฉื ืœืขื•ืจืง ื”ืจืืฉื™,
4
4
3
66
11,776
Matan Arbel-Groissman retweeted
1/ Lab automation is insanely mispriced. Today I visited a London-based biomaterials startup running large-scale bacterial screens. They use a colony picker that costs $95,000
18
17
12
269
42,032
ืงืฆืช ืžื“ืข ืœืืกืงืคื™ื–ื: ื™ืฉื ื ื›ื™ืžื™ื›ืœื™ื ืฉื ืงืจืื™ื PFAS ืฉื”ื™ื ื ื‘ืฉื™ืžื•ืฉ ืชืขืฉื™ื™ืชื™ ื ืจื—ื‘. ื˜ืคืœื•ืŸ ื”ื•ื ืื—ื“ ืžื”ื. ืžื›ื™ื•ื•ืŸ ืฉื”ื ื›"ื› ื™ืฆื™ื‘ื™ื, ื‘ื™ืŸ ื”ืฉืืจ ื‘ื’ืœืœ ืงืฉืจื™ ืคื—ืžืŸ-ืคืœื•ืื•ืจ, ื”ื ื ื—ืฉื‘ื™ื ืœ"ื›ื™ืžื™ื›ืœื™ ื ืฆื—" ืฉืžืชืคืจืงื™ื ืœืื˜ ืžืื“ ื•ืžื–ื”ืžื™ื ื›ืš ืืช ื”ืกื‘ื™ื‘ื”. ืœื—ืœืงื ื™ืฉ ื–ืžืŸ ืžื—ืฆื™ืช ื—ื™ื™ื ืฉืœ 8 ืฉื ื™ื ื‘ื’ื•ืฃ ืฉืœื ื•. ื—ืœืงื ืงืฉื•ืจื™ื ื‘ืžื—ืœื•ืช ืื ื›ื™
1
1
15
1,702
Matan Arbel-Groissman retweeted
Iโ€™ve seen alot of posts recently about pancreatic cancer being โ€œcuredโ€ in mice. Just a general reminder of something that is currently hung in my office:
2
15
114
9,825
Matan Arbel-Groissman retweeted
ื”ืžืืžืจ ื”ื—ื“ืฉ ืฉืœื ื• ืขืœ ืชื•ืจืฉืชื™ื•ืช ืชื•ื—ืœืช ื”ื—ื™ื™ื ืคื•ืจืกื ื‘-@ScienceMagazine ื•ื–ื›ื” ืœืœื ืžืขื˜ ื—ืฉื™ืคื” ืชืงืฉื•ืจืชื™ืช. ื”ื’ื™ืข ื”ืขืช ืœืฉืจืฉื•ืจ ื‘ืขื‘ืจื™ืช! ื‘ืžืฉืš ืขืฉื•ืจื™ื, ืฉืœื˜ ื”ืงื•ื ืฆื ื–ื•ืก ืฉื’ื ื˜ื™ืงื” ืžืกื‘ื™ืจื” ืจืง ื›-20-25% ืžื”ื”ื‘ื“ืœื™ื ื‘ืžืฉืš ื”ื—ื™ื™ื ื‘ื™ืŸ ืื ืฉื™ื. ืœืื—ืจ ืฉืœืงื—ื ื• ื‘ื—ืฉื‘ื•ืŸ "ืชืžื•ืชื” ื—ื™ืฆื•ื ื™ืช", ืžืฆืื ื• ืฉื”ืžืกืคืจ ืงื•ืคืฅ ืœ-50%.
8
16
212
12,832
Matan Arbel-Groissman retweeted
It just seems implausible this is what we are made of, essentially, nanotechnology about a billion years beyond anything we can design or make ourselves.
1,582
6,478
1,390
51,913
8,604,854
Matan Arbel-Groissman retweeted
Our new paper on reassessing the heritability of human lifespan is out in @ScienceMagazine! ๐Ÿงฌ For decades, the consensus has been that genetics explains just 20โ€“25% of lifespan differences. We found that after accounting for extrinsic mortality, that number jumps to ~50%. A ๐Ÿงต
30
265
48
1,288
459,166